Cardiometabolic Diseases Market Size & Opportunity 2028

report image

Cardiometabolic Diseases Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Cardiovascular Disease (CVD), Type 2 diabetes, Hypertension, and Obesity), Treatment (ACE Inhibitors, Diuretics, Glucophage, and Others), Dosage (Tablet and Injection), Route of Administration (Oral and Intravenous), End Users (Hospital, Clinic, and Homecare Setting), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Geography

Publication Month: Oct 2021 | Report Code: TIPRE00025374 | No. of Pages: 293 | Category: Pharmaceuticals | Status: Published

The cardiometabolic diseases market is expected to reach US$ 121,804.49 million by 2028 from US$ 93,494.41 million in 2021; it is estimated to grow at a CAGR of 3.9% during 2021–2028.

Cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are a few symptoms of cardiometabolic diseases. Individuals suffering from cardiometabolic syndrome are prone to many other life-threatening diseases, such as type 2 diabetes, stroke, coronary artery disease (CAD), and cardiovascular disease (CVD). Both genetic and environmental conditions are responsible for the development of the diseases.

Strategic Insights

Report Coverage - Cardiometabolic Diseases Market
Report CoverageDetails
Market Size Value inUS$ 93,494.41 million in 2021
Market Size Value byUS$ 121,804.49 million by 2028
Growth rateCAGR of 3.9% during 2021 from 2028
Forecast Period2021-2028
Base Year2021
No. of Pages293
No. of Tables165
No. of Charts & Figures84
Historical data availableYes
Segments coveredType, Treatment, Dosage, Route of Administration, End Users, Distribution Channel, and Geography
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

The cardiometabolic diseases market growth is mainly attributed to factors such as increasing prevalence of cardiometabolic diseases and innovation in CMDs therapeutics. However, underdiagnosisof CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market.

Lucrative Regions in Cardiometabolic Diseases Market

Lucrative Regions in Cardiometabolic Diseases Market

Get more information on this report :


Market Insights
Increasing Prevalence of Cardiometabolic Diseases

Cardiometabolic diseases (CMDs) are one of the leading causes of death worldwide. These diseases are mainly caused by an unhealthy lifestyle, physical inactivity, smoking, and an unhealthy diet. CMDs include cardiovascular diseases (CVDs), diabetes mellitus, and chronic renal failure. As per the WHO, around 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.

Most cardiovascular diseases can be prevented by addressing behavioral risk factors, such as tobacco intake, unhealthy dietary choices, obesity, physical inactivity, and alcohol consumption. Diabetes is one of the life-threatening chronic diseases with no functional cure. It leads to various complications and increases the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As per the International Diabetes Federation (IDF), in 2019, ~463 million adults were living with diabetes, which is expected to reach 700 million by 2045.

There is a global rise in the number of people having one or more CMDs due to increasing smoking, lack of exercise, alcohol consumption, and unhealthy food habits. As per the WHO July 2021 stats, more than 8 million people die every year due to tobacco consumption. Its consumption is higher in low- and middle-income countries, with 80% of its global consumer base living in these countries. The increasing prevalence of obesity is giving rise to the patient base suffering from CMDs as well. With this rapid upswing in the prevalence of CMDs, the need for appropriate cardiometabolic disease treatments has skyrocketed, resulting in tremendous growth of the market.

Type-Based Insights

The cardiometabolic diseases market, by type, is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. The cardiovascular disease (CVD) segment held the largest share of the market in 2021, and the segment is anticipated to register the highest CAGR in the market during the forecast period.

Cardiometabolic Diseases Market, by Type – 2021 and 2028

Cardiometabolic Diseases Market, by Type – 2021 and 2028

Get more information on this report :


Treatment-Based Insights

By treatment, the cardiometabolic diseases market is segmented into ACE inhibitors, diuretics, Glucophage, and others. The ACE inhibitors segment held the largest share of the market in 2021, and the same segment is anticipated to register the highest CAGR  in the market during the forecast period.

Dosage-Based Insights

The cardiometabolic diseases market, by dosage, is bifurcated into tablet and injection. The tablet segment held a larger market share in 2021 and is anticipated to register a higher CAGR in the market during the forecast period.

Route of Administration-Based Insights

The cardiometabolic diseases market, by route of administration, is bifurcated into oral and intravenous. In 2021, the oral segment held a larger share of the market and is expected to register a higher CAGR in the coming years.

End Users-Based Insights

The cardiometabolic diseases market, by end users, is segmented into clinic, hospital, and homecare setting. In 2021, the hospital segment held the largest share of the market and is anticipated to register the highest CAGR  in the market during the forecast period.


Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the laboratory developed test market players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name globally.

The report segments cardiometabolic diseases market as follows

Based on type, the cardiometabolic diseases market is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. Based on treatment, the market is segmented into ACE inhibitors, diuretics, Glucophage, and others. Based on dosage, the cardiometabolic diseases market is bifurcated into tablet and injection. Based on route of administration, the market is bifurcated into oral and intravenous. Based on end users, the cardiometabolic diseases market is segmented into clinic, hospital, and homecare setting. By geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East and Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Company Profiles

  • Eli Lilly and Company
  • Bayer AG
  • Arrowhead Pharmaceuticals, Inc
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/S
  • AstraZeneca
  • Alnylam Pharmaceuticals, Inc.
  • Cardax, Inc
  • Kowa Company, Ltd.

Frequently Asked Questions

Cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are a few symptoms of cardiometabolic diseases. Individuals suffering from cardiometabolic syndrome are prone to many other life-threatening diseases, such as type 2 diabetes, stroke, coronary artery disease (CAD), and cardiovascular disease (CVD). Both genetic and environmental conditions are responsible for the development of the diseases.
The factors that are driving and restraining factors that will affect cardiometabolic diseases market in the coming years. Factors such as increasing prevalence of cardiometabolic diseases and innovation in CMDs therapeutics. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market.
The cardiometabolic diseases market majorly consists of the players such as as Eli Lilly and Company; Bayer AG; Arrowhead Pharmaceuticals, Inc; Novartis AG; Boehringer Ingelheim International GmbH; Novo Nordisk A/S; AstraZeneca; Alnylam Pharmaceuticals, Inc.; Cardax, Inc.; and Kowa Company, Ltd among others.
The global cardiometabolic diseases market cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. The cardiovascular disease (CVD) segment is expected to hold the largest share and register the highest CAGR in the market during the forecast period.

The List of Companies - Cardiometabolic Diseases Market

  1. Eli Lilly and Company
  2. Bayer AG
  3. Arrowhead Pharmaceuticals, Inc
  4. Novartis AG
  5. Boehringer Ingelheim International GmbH
  6. Novo Nordisk A/S
  7. AstraZeneca
  8. Alnylam Pharmaceuticals, Inc.
  9. Cardax, Inc
  10. Kowa Company, Ltd.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the cardiometabolic diseases market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPRE00025374
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




christmas_festive_offer

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000 $2700
  • $4550 $4095
  • $6550 $5568
  • $8550 $6840

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount